VSIR and neoplasm: All in all, VISTA blockade exhibits synergistic anti-tumor effects with anti-PD-(L)1 treatment, and this might be due to that VISTA blockade improves T cell infiltration and reduces the resistance to anti-PD-(L)1 treatment via increasing the production of IFN-γ.